CLAIMS

1. A *H. pylori* protein or derivative or fragment or mutant or variant thereof capable of inhibiting the activation of NF-kB.

5

- 2. A *H. pylori* protein as claimed in claim 1 wherein the protein is a thioredoxin or derivative or fragment or mutant or variant thereof.
- 3. A *H. pylori* protein as claimed in claim 1 wherein the protein has the following amino acid sequence:

MSHYIELTEE NFESTIKKGV ALVDFWAPWC GPCKMLSPVI DELASEYEGK AKICKVNTDE QEELSAKFGI RSIPTLLFTK DGEVVHQLVG VQTKVALKEQ LNKLLG

15

- 4. A thioredoxin or derivative or fragment or mutant or variant thereof containing the redox active peptide sequence CGPC.
- 5. Prokaryotic or eukaryotic thioredoxins having potent immune-suppressive effects.
 - 6. Polypeptides containing the redox active peptide sequence CGPC.
 - 7. A H. pylori protein having the following amino acid sequence:

25

MSHYIELTEE	NFESTIKKGV	ALVDFWAPWC	GPCKMLSPVI
DELASEYEGK	AKICKVNTDE	QEELSAKFGI	RSIPTLLFTK
DGEVVHQLVG	VQTKVALKEQ	LNKLLG	

30 8. A derivative or fragment or mutant or variant of the protein of claim 7.

- 9. Use of a *H. pylori* thioredoxin protein or derivative or fragment or variant thereof as claimed in claim 1 in the prevention and/or treatment of inflammation.
- 5 10. Use of a *H. pylori* thioredoxin protein or derivative or fragment or variant thereof as claimed in claim 9 in the prevention and/or treatment of inflammatory bowel disease.
- 11. Use of a *H. pylori* thioredoxin protein or derivative or fragment or variant thereof as claimed in claim 9 in the prevention and/or treatment of rheumatoid/autoimmune arthritis.

15

20

- 12. Use of a *H. pylori* thioredoxin protein or derivative or fragment or variant thereof as claimed in claim 9 in the prevention and/or treatment of any chronic disease wherein NF-κB is transcriptionally activated.
 - 13. Use as claimed in claim 11 for the prevention and/or treatment of any one or more of autoimmune arthritis or other autoimmune diseases, asthma, septic shock, lung fibrosis, glomerulonephritis, atherosclerosis or autoimmune encephalomyelitis.
 - 14. Use of a *H. pylori* thioredoxin protein or derivative or fragment or mutant or variant thereof as claimed in any preceding claim in soft tissue injury.
- 15. A *H. pylori* thioredoxin protein or derivative or fragment or mutant or variant thereof as claimed in claim 1 for use in the preparation of a medicament for the treatment and/or prophylaxis of any chronic disease wherein NF-κB is transcriptionally activated.

16. A protein as claimed in claim 1 for use in the preparation of a medicament for the treatment and/or prophylaxis of any chronic disease wherein NF-κB is transcriptionally activated.

5